



For Treatment of PD-L1+
Metastatic Triple-Negative
Breast Cancer



On behalf of Genentech, you are invited to
attend an expert-led educational presentation

TECENTRIQ: The First Cancer Immunotherapy Approved for PD-L1– Positive Metastatic Triple-Negative Breast Cancer (mTNBC)

Wednesday, May 08, 2019

Registration: 6:00 PM Pacific

Dinner and Program: 6:30 PM Pacific

LB Steak

334 Santana Row

#1000

San Jose, CA 95128

Featured Faculty

Debbie Tuttle, DNP, FNP-BC, AOCNS, CBCN

Oncology Nurse Practitioner

Stanford Cancer Center

Palo Alto, CA

INDICATION AND USAGE

TECENTRIQ in combination with paclitaxel protein-bound is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering $\geq 1\%$ of the tumor area), as determined by an FDA-approved test.

This indication is approved under accelerated approval based on progression free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial(s).

Minnesota, New Jersey, Vermont, and Federal Entities (e.g., the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.

When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (e.g., meals, valet parking) at the program. If you choose to opt out you may either pay for the meal and parking on your own, or not consume anything at the program.

For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit sunshine.gene.com).

The meal cost may vary by event location and be up to \$150 per person (exceptions may apply).

Please see accompanying full Prescribing Information and reverse for Important Safety Information

PROGRAM OBJECTIVES:

- Covers the key statistics and risk factors for TNBC, discusses the proposed mechanism of action, outlines PD-L1 testing in mTNBC, reviews the efficacy and safety of IMPassion130, and discusses adverse event management for treatment with TECENTRIQ
- Includes information on TECENTRIQ dosing and administration, Genentech patient support programs, and a patient case.

Please RSVP by Wednesday, May 01, 2019

Lisa Reinmann at (415) 297-8278

or reinmann.lisa@gene.com

Renita Vance MSN RN at (206) 369-6897

or vance.renita@gene.com

or at www.geniersvp.com/SGEN23969

Genentech
A Member of the Roche Group

© 2019 Genentech USA, Inc. All rights reserved. PDL/013019/0039 Printed in USA.

IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-mediated pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-mediated hepatitis.** Immune-mediated hepatitis and liver test abnormalities, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal
- **Immune-mediated colitis.** Immune-mediated diarrhea or colitis have occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-mediated endocrinopathies.** Thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, including diabetic ketoacidosis, and hypophysitis/hypopituitarism have occurred
- **Other immune-mediated adverse reactions.** TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ
- **Infections.** Severe infections, including fatal cases, have occurred
- **Infusion-related reactions.** Severe or life-threatening infusion-related reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Verify pregnancy status prior to initiating TECENTRIQ. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions (rate $\geq 20\%$) in patients receiving TECENTRIQ with paclitaxel protein-bound for mTNBC were alopecia (56%), peripheral neuropathies (47%), fatigue (47%), nausea (46%), diarrhea (33%), anemia (28%), constipation (25%), cough (25%), headache (23%), neutropenia (21%), vomiting (20%), and decreased appetite (20%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

This event is sponsored by Genentech USA, Inc. No continuing education credits are offered with this program.

This presentation is intended for US healthcare providers only.

Nab-paclitaxel (nab-pac) is also referred to as paclitaxel protein-bound